Precision treatment for cancer: Role of prognostic and predictive markers
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Precision treatment for cancer: Role of prognostic and predictive markers
Authors
Keywords
-
Journal
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
Volume 51, Issue 1, Pages 30-45
Publisher
Informa UK Limited
Online
2014-01-16
DOI
10.3109/10408363.2013.865700
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor-Positive, HER2-Negative Breast Cancer: Challenges and Considerations
- (2017) Gayathri Nagaraj et al. Journal of the National Comprehensive Cancer Network
- Using Multigene Tests to Select Treatment for Early-Stage Breast Cancer
- (2017) Rodrigo Goncalves et al. Journal of the National Comprehensive Cancer Network
- Personalized adjuvant therapies: Lessons from the past
- (2013) Aron Goldhirsch BREAST
- Optimized immunohistochemistry in combination with image analysis: A reliable alternative to quantitative ELISA determination of uPA and PAI-1 for routine risk group discrimination in breast cancer
- (2013) D.S. Lang et al. BREAST
- A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer
- (2013) Pia Bükmann Larsen et al. CANCER TREATMENT REVIEWS
- Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action
- (2013) V. Heinemann et al. CANCER TREATMENT REVIEWS
- Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer
- (2013) M. J. Duffy et al. CLINICAL CHEMISTRY
- Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients
- (2013) N. Harbeck et al. EUROPEAN JOURNAL OF CANCER
- Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2013) Sara A. Hurvitz et al. JOURNAL OF CLINICAL ONCOLOGY
- ERCC1 and RRM1: Ready for Prime Time?
- (2013) Benjamin Besse et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
- (2013) Chee Khoon Lee et al. JNCI-Journal of the National Cancer Institute
- The Implications of Clonal Genome Evolution for Cancer Medicine
- (2013) Samuel Aparicio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
- (2013) Chih-Chieh Chen et al. PLoS One
- Activating Mutations in HER2 : Neu Opportunities and Neu Challenges
- (2013) Britta Weigelt et al. Cancer Discovery
- Prostate cancer screening and the management of clinically localized disease
- (2013) T. J. Wilt et al. BMJ-British Medical Journal
- Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research
- (2013) Richard D. Riley et al. PLOS MEDICINE
- Prognosis Research Strategy (PROGRESS) 3: Prognostic Model Research
- (2013) Ewout W. Steyerberg et al. PLOS MEDICINE
- Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
- (2012) M. S. N. Mohd Sharial et al. ANNALS OF ONCOLOGY
- Reliability of core needle biopsy for determining ER and HER2 status in breast cancer
- (2012) T. J. A. Dekker et al. ANNALS OF ONCOLOGY
- Her2/neu testing in gastric cancer: evaluating the risk of sampling errors
- (2012) V. S. Warneke et al. ANNALS OF ONCOLOGY
- Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics
- (2012) H Ballentine Carter ASIAN JOURNAL OF ANDROLOGY
- Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
- (2012) Dorte L. Nielsen et al. BREAST
- Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?
- (2012) Atocha Romero et al. Clinical & Translational Oncology
- Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development
- (2012) G. Poste et al. CLINICAL CANCER RESEARCH
- New Strategies in Melanoma: Molecular Testing in Advanced Disease
- (2012) Scott E. Woodman et al. CLINICAL CANCER RESEARCH
- Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
- (2012) A. M. Menzies et al. CLINICAL CANCER RESEARCH
- The current status of S-100B as a biomarker in melanoma
- (2012) S. Kruijff et al. EJSO
- Microarrays and cancer diagnosis
- (2012) Manjul Tiwari Journal of Cancer Research and Therapeutics
- Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting
- (2012) Lisa M. McShane et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
- (2012) Linda Sofie Lindström et al. JOURNAL OF CLINICAL ONCOLOGY
- Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective
- (2012) Umberto Malapelle et al. JOURNAL OF CLINICAL PATHOLOGY
- Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer
- (2012) A. D. Roth et al. JNCI-Journal of the National Cancer Institute
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- (2012) Christina Davies et al. LANCET
- Optimising therapy for EGFR-addicted NSCLC: just the start
- (2012) Ramaswamy Govindan et al. LANCET ONCOLOGY
- Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
- (2012) Michael Untch et al. LANCET ONCOLOGY
- Tumor Markers in Clinical Practice: A Review Focusing on Common Solid Cancers
- (2012) Michael J. Duffy MEDICAL PRINCIPLES AND PRACTICE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy
- (2012) Kun Wang et al. TUMOR BIOLOGY
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX
- (2011) S. Aebi et al. ANNALS OF ONCOLOGY
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
- (2011) Elisabeth Luporsi et al. BREAST CANCER RESEARCH AND TREATMENT
- First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations
- (2011) Takayuki Iwamoto et al. BREAST CANCER RESEARCH AND TREATMENT
- KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
- (2011) N Knijn et al. BRITISH JOURNAL OF CANCER
- The role of Tau protein in resistance to paclitaxel
- (2011) Marta Smoter et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- EGFR Mutations, Gene Amplification, and Protein Expression and KRAS Mutations in Primary and Metastatic Tumors of Nonsmall Cell Lung Cancers and Their Clinical Implications: A Meta-Analysis
- (2011) Chengbo Han et al. CANCER INVESTIGATION
- EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects
- (2011) Jean-Charles Soria et al. CANCER TREATMENT REVIEWS
- New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available
- (2011) V. Abramson et al. CLINICAL CANCER RESEARCH
- A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer
- (2011) Thierry Petit et al. ENDOCRINE-RELATED CANCER
- A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer
- (2011) Barbara-Ann Adelstein et al. EUROPEAN JOURNAL OF CANCER
- Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue
- (2011) Richard D. Kennedy et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation Study of a Quantitative Multigene Reverse Transcriptase–Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer
- (2011) Richard G. Gray et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
- (2011) Vicki Leigh Keedy et al. JOURNAL OF CLINICAL ONCOLOGY
- A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer
- (2011) Peter M. Ellis et al. Journal of Thoracic Oncology
- Gene expression profiling in breast cancer: classification, prognostication, and prediction
- (2011) Jorge S Reis-Filho et al. LANCET
- Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
- (2011) Meredith M Regan et al. LANCET ONCOLOGY
- BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
- (2011) E. R. Cantwell-Dorris et al. MOLECULAR CANCER THERAPEUTICS
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials
- (2011) Wenjin Yin et al. PLoS One
- Markersysteme beim Hodentumor
- (2011) S. Krege et al. UROLOGE
- Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?
- (2011) M. J. Duffy ANNALS OF CLINICAL BIOCHEMISTRY
- Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) A. Horwich et al. ANNALS OF ONCOLOGY
- CA 15-3: Uses and limitation as a biomarker for breast cancer
- (2010) Michael J. Duffy et al. CLINICA CHIMICA ACTA
- Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1
- (2010) Manfred Schmitt et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- (2010) Wendy De Roock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
- (2010) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
- (2010) Alberto Bardelli et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors
- (2010) Timothy D. Gilligan et al. JOURNAL OF CLINICAL ONCOLOGY
- Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
- (2010) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
- (2010) M. Elizabeth H. Hammond et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer
- (2010) Ramon Salazar et al. JOURNAL OF CLINICAL ONCOLOGY
- Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
- (2010) Jonas N Søndergaard et al. Journal of Translational Medicine
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
- (2010) Jack Cuzick et al. LANCET ONCOLOGY
- Breast cancer assessment tools and optimizing adjuvant therapy
- (2010) Catherine Oakman et al. Nature Reviews Clinical Oncology
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor-Positive Metastatic Breast Cancer
- (2010) L. S. Schwartzberg et al. ONCOLOGIST
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group
- (2009) Steven M Teutsch et al. GENETICS IN MEDICINE
- Pretreatment Prostate-Specific Antigen Velocity and the Risk of Death From Prostate Cancer in the Individual With Low-Risk Prostate Cancer
- (2009) Anthony V. D'Amico et al. JOURNAL OF CLINICAL ONCOLOGY
- Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer
- (2009) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
- (2009) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Feasibility of Measuring the Prognostic Factors uPA and PAI-1 in Core Needle Biopsy Breast Cancer Specimens
- (2009) Christoph Thomssen et al. JNCI-Journal of the National Cancer Institute
- Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
- (2009) R. M. Simon et al. JNCI-Journal of the National Cancer Institute
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
- (2009) Kathy S Albain et al. LANCET ONCOLOGY
- MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
- (2009) Michael Weller et al. Nature Reviews Neurology
- HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer
- (2008) M. F. Press et al. CLINICAL CANCER RESEARCH
- National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
- (2008) C. M. Sturgeon et al. CLINICAL CHEMISTRY
- Prostate-Specific Antigen (PSA) and PSA Velocity: Competitors or Collaborators in the Prediction of Curable and Clinically Significant Prostate Cancer
- (2008) Anthony V. D'Amico JOURNAL OF CLINICAL ONCOLOGY
- Chemoendocrine Compared With Endocrine Adjuvant Therapies for Node-Negative Breast Cancer: Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors—International Breast Cancer Study Group
- (2008) Giuseppe Viale et al. JOURNAL OF CLINICAL ONCOLOGY
- Prostate Specific Antigen Kinetics in the Management of Prostate Cancer
- (2008) Shomik Sengupta et al. JOURNAL OF UROLOGY
- Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time
- (2008) Philip M. Arlen et al. JOURNAL OF UROLOGY
- Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study
- (2008) Kerby Shedden et al. NATURE MEDICINE
- High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
- (2008) D. Santini et al. ONCOLOGIST
- PSA Velocity Is Associated With Gleason Score in Radical Prostatectomy Specimen: Marker for Prostate Cancer Aggressiveness
- (2008) Stacy Loeb et al. UROLOGY
- Do we need more nomograms for predicting outcomes in patients with prostate cancer?
- (2008) Michael W Kattan Nature clinical practice. Urology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now